MAPT and Alzheimer disease: Specifically, in diabetes-related Alzheimer’s disease (AD), GLP-1 enhances mitochondrial biogenesis and the antioxidant defense system by modulating the PGC-1α signaling pathway, directly mitigating tau hyperphosphorylation [36].